AUG 3, 2026 · PHASE 1/2 TRIAL
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
ClinicalTrials.gov
This is an active interventional trial combining a radiopharmaceutical with chemotherapy and immunotherapy in ES-SCLC; no results are posted in this registry record, and the study aims only to establish safety and preliminary efficacy.
Reported
Planned enrollment55
Phase 1b primary outcomeFrequency of dose limiting toxicities (DLTs…
Phase 2 primary outcomeOverall survival (OS) from date of randomiz…